Influenza B NA Antibody (MAb B19): sc-66056

Influenza B NA Antibody (MAb B19) is a mouse monoclonal IgG2a antibody that detects the Influenza B NA protein of Influenza B Virus origin by western blotting (WB). Anti-Influenza B NA antibody (MAb B19) is available as a non-conjugated format, providing researchers with a reliable tool for studying this critical viral component. The neuraminidase protein plays a vital role in the life cycle of the Influenza B virus by facilitating the release of newly formed viral particles from infected cells, thereby promoting viral spread and infection. This enzymatic activity is essential for the virus to propagate and evade the host′s immune response, making neuraminidase a key target for antiviral therapies. Influenza viruses, which include Influenza A, B, and C, are RNA viruses belonging to the Orthomyxoviridae family and are known for their ability to undergo antigenic shifts and drifts, allowing them to escape immune detection. While Influenza A is notorious for causing pandemics, Influenza B typically results in milder illnesses, such as seasonal flu, underscoring the importance of understanding its viral proteins for effective treatment and prevention strategies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Influenza B NA Antibody (MAb B19) References:

1. Coinfection with influenza B virus does not affect association of Neisseria meningitidis with human nasopharyngeal mucosa in organ culture.  |  Read, RC., et al. 1999. Infect Immun. 67: 3082-6. PMID: 10338524
2. Influenza B virus in seals.  |  Osterhaus, AD., et al. 2000. Science. 288: 1051-3. PMID: 10807575
3. Influenza B and C virus NEP (NS2) proteins possess nuclear export activities.  |  Paragas, J., et al. 2001. J Virol. 75: 7375-83. PMID: 11462009
4. Influenza A and B virus infections in children.  |  Peltola, V., et al. 2003. Clin Infect Dis. 36: 299-305. PMID: 12539071
5. Epidemics of two Victoria and Yamagata influenza B lineages in Yamagata, Japan.  |  Mizuta, K., et al. 2004. Epidemiol Infect. 132: 721-6. PMID: 15310174
6. Detection and characterization of new influenza B virus variants in 2002.  |  Chi, XS., et al. 2005. J Clin Microbiol. 43: 2345-9. PMID: 15872264
7. Sequential mutations in hemagglutinins of influenza B virus isolates: definition of antigenic domains.  |  Krystal, M., et al. 1983. Proc Natl Acad Sci U S A. 80: 4527-31. PMID: 6192436
8. Serological diagnosis of influenza B virus infection: comparison of an enzyme-linked immunosorbent assay and the hemagglutination inhibition test.  |  Turner, R., et al. 1982. J Clin Microbiol. 15: 824-9. PMID: 7047553

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Influenza B NA Antibody (MAb B19) has 0 citations in a variety of scientific publications.

Primary antibodies for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Influenza B NA Antibody (MAb B19) Specifications

Alternate Product Name: Influenza B NA

Product Clone Name: MAb B19

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a

Amino Acids:

Epitope Target: Influenza B NA

Epitope Species: Influenza B Virus

Product Reactivity/Detection: neuraminidase (NA)

Species Reactivity/Detection: Influenza B Virus

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB

Vialing Information: Each vial contains 100 µg IgG_2a in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for Influenza B NA Antibody (MAb B19): N/A